{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013169","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.552811+00:00","generated_at":"2026-06-17T00:36:19.104085+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Precision BioSciences reports ~$158M cash; DMD gene editing abstract accepted at ASGCT","bullets":["Expects ~$158M cash as of March 31, 2023; cash runway through Q1 2025.","PBGENE-DMD preclinical data selected for oral presentation at ASGCT May 2023.","ARCUS nucleases designed to excise ~500k bp mutation hot spot in dystrophin gene.","Abstract available May 2, 2023 on ASGCT website."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013169","json":"https://secwatch.observer/filing/0000950170-23-013169.json","markdown":"https://secwatch.observer/filing/0000950170-23-013169.md","text":"https://secwatch.observer/filing/0000950170-23-013169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/0000950170-23-013169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/dtil-20230418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:36:19.104085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4e09c0edb39f71723cfd5d21840e4215d7baad7","claim":"PRECISION BIOSCIENCES INC reported preliminary financial results for the quarter ended March 31, 2023.","evidence_excerpt":"Although it has not finalized its full financial results for the quarter ended March 31, 2023, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $158 million in cash and cash equivalents as of March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/0000950170-23-013169-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}